Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Cadence Pharmaceuticals Inc. et al. v. Exela Pharma Sciences LLC et al.
Case Number:
1:11-cv-00733
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
December 03, 2013
Exela Tries To Escape Ruling, Nix Painkiller Patent Again
Exela Pharma Sciences LLC and its subsidiaries asked a Delaware federal judge to reconsider a recent ruling that they infringed Cadence Pharmaceuticals Inc.'s patents by creating a generic version of injectable-painkiller Ofirmev, saying Monday that new evidence proved one of the patents invalid.
-
November 22, 2013
Cadence Prevails Against Exela In Generic Ofirmev Row
A Delaware federal judge has ruled against Exela Pharma Sciences LLC and its subsidiaries in favor of Cadence Pharmaceuticals Inc. in a patent infringement suit over plans to market a generic version of the injectable pain reliever Ofirmev, according to an opinion unsealed on Friday.
-
December 10, 2012
Del. Court Asks France To Compel Bristol-Myers VP's Testimony
A Delaware federal judge on Friday asked the French government for help in deposing a Bristol-Myers Squibb Co. executive believed by Cadence Pharmaceuticals Inc. to have information critical to its pursuit of patent infringement claims over injectable acetaminophen treatment Ofirmev.
-
November 28, 2012
Perrigo Settles With Cadence Over Ofirmev Generic Plans
Generic-drug maker Perrigo Co. and its subsidiary Paddock Laboratories LLC have entered into a licensing agreement with Cadence Pharmaceuticals Inc., ending a Delaware patent dispute over Paddock's plans to make a generic version of Cadence's Ofirmev brand of injectable acetaminophen, the companies announced Wednesday.
-
August 19, 2011
Cadence Sues Exela, Paddock To Block Generic Ofirmev
Cadence Pharmaceuticals Inc. launched a patent infringement suit against generics makers Paddock Laboratories Inc. and Exela Pharma Sciences LLC in Delaware federal court on Thursday, seeking to block a generic version of Ofirmev, an injectable form of the pain reliever acetaminophen.